NeuroPace Issues 2025 Financial Guidance Targets Mountain View, Calif. – NeuroPace, Inc. (Nasdaq: NPCE) held a blended in-person and virtual Investor Day on January 28, 2025, in New York, New York, where it outlined its market, product, and clinical

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NeuroPace’s 8K filing here.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.